Otomagnetics
Otomagnetics is developing a non-invasive magnetic drug delivery system aimed at delivering therapies to the inner and middle ear, eye, and skin. Their proprietary technology uses magnetic injection with biodegradable magnetic particles to treat various conditions, including hearing loss, tinnitus, middle ear infections, and eye diseases like macular degeneration. The company focuses on creating innovative, non-invasive solutions to address unmet medical needs across large markets.
Industries
Nr. of Employees
small (1-50)
Otomagnetics
Bethesda, Maryland, United States, North America
Patents
Magnetic injection of therapeutic agents by addition of material extrusions with differing magnetization and magnetic permeability
US-11484694-B2
View Details
Magnetic injection of therapeutic agents by addition of material extrusions with differing magnetization and magnetic permeability
US-11484694-B2
View DetailsProducts
Magnetic injection delivery platform (device + biodegradable magnetic particles)
A platform combining a magnetic injector device with biodegradable magnetic particles formulated for injection. Designed to deliver therapeutic payloads non‑invasively to inner ear, middle ear, retinal and cutaneous targets in preclinical studies.
magnetic injection delivery system
A proprietary device combining a magnetic injector with biodegradable magnetic particles to carry drugs, proteins, or genes, aimed at transforming drug delivery.
Otomagnetics proprietary magnetic injection system
A non-invasive method to deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin using magnetic delivery technology.
Magnetic injection delivery platform (device + biodegradable magnetic particles)
A platform combining a magnetic injector device with biodegradable magnetic particles formulated for injection. Designed to deliver therapeutic payloads non‑invasively to inner ear, middle ear, retinal and cutaneous targets in preclinical studies.
magnetic injection delivery system
A proprietary device combining a magnetic injector with biodegradable magnetic particles to carry drugs, proteins, or genes, aimed at transforming drug delivery.
Otomagnetics proprietary magnetic injection system
A non-invasive method to deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin using magnetic delivery technology.
Services
Collaboration with pharmaceutical companies, advocacy groups, foundations and other organizations for co‑development, licensing or joint research related to magnetic nanoparticle delivery.
Collaboration with pharmaceutical companies, advocacy groups, foundations and other organizations for co‑development, licensing or joint research related to magnetic nanoparticle delivery.
Expertise Areas
- Non‑invasive targeted drug delivery
- Nanoparticle formulation for injectable use
- Preclinical development and animal‑model efficacy testing
- Otic (inner and middle ear) therapeutics
Key Technologies
- Magnetic field‑directed targeting
- Biodegradable magnetic nanoparticles
- Magnetically guided injectable delivery
- Payload loading for small molecules, proteins and genes
News & Updates
In the biotechnology space, only a handful of companies manage to cut through the noise and successfully achieve their full potential in the midst of increasingly complex and volatile conditions.
Abhita Batra, a young and visionary scientist - turned Chief Executive Officer - is on a quest to successfully re-imagine patient experience.
Bryce Ross reports on a startup working to enhance children's health and well-being.
An article discussing Otomagnetics' innovative approach to treating childhood cancer survivors using magnetic drug delivery.
Otomagnetics received a significant NIH/NCI SBIR contract to develop a drug delivery system aimed at preventing hearing loss in pediatric cancer patients.
In the biotechnology space, only a handful of companies manage to cut through the noise and successfully achieve their full potential in the midst of increasingly complex and volatile conditions.
Abhita Batra, a young and visionary scientist - turned Chief Executive Officer - is on a quest to successfully re-imagine patient experience.
Bryce Ross reports on a startup working to enhance children's health and well-being.
An article discussing Otomagnetics' innovative approach to treating childhood cancer survivors using magnetic drug delivery.
Otomagnetics received a significant NIH/NCI SBIR contract to develop a drug delivery system aimed at preventing hearing loss in pediatric cancer patients.